Dedifferentiated liposarcoma with leukocytosis. A case report of G-CSF-producing soft-tissue tumors, possible association with undifferentiated liposarcoma lineage
© Sakamoto et al; licensee BioMed Central Ltd. 2007
Received: 27 May 2007
Accepted: 16 November 2007
Published: 16 November 2007
Granulocyte-colony-stimulating factor (G-CSF) functions as a hematopoietic growth factor and it is responsible for leukocytosis. G-CSF-producing tumors associated with leukocytosis include various types of malignancies.
We report the case of a 72-year-old man with dedifferentiated liposarcoma characterized by dedifferentiated components of malignant fibrous histiocytoma (MFH)-like features in addition to well-differentiated lipoma-like liposarcoma, arising from his upper arm. Preoperative laboratory data showed leukocytosis (103,700/μl). The serum level of G-CSF was also elevated (620 pg/ml [normal, <8 pg/ml]). Nine days after the surgery, the leukocytosis was relieved (WBC; 6,920/μl) and the elevated serum G-CSF level was significantly decreased (G-CSF; 12 pg/ml). One month after the surgery, leukocytosis gradually began to appear again. Three months after the surgery metastatic lung lesions were confirmed, and the patient subsequently died of respiratory problems. In the English literature regarding soft-tissue tumors with leukocytosis, including the current case, we could review a total of 6 cases of liposarcoma with leukocytosis. The subtype of these 6 liposarcoma cases was undifferentiated liposarcoma, comprising dedifferentiated liposarcoma in 4 cases and pleomorphic liposarcoma in 2 cases.
Since the only other soft-tissue tumor that was associated with leukocytosis was MFH, and since MFH is characterized by the absence of any specific differentiation, we would like to propose a possible association between G-CSF-producing soft-tissue tumors and an undifferentiated liposarcoma lineage, such as dedifferentiated liposarcoma or pleomorphic liposarcoma.
Granulocyte-colony-stimulating factor (G-CSF) enhances differentiation along the neutrophil lineage, and accelerates maturation of metamyelocytes into mature neutrophils. Consequently, G-CSF is known to function as a hematopoietic growth factor and it is known to be responsible for leukocytosis. G-CSF-producing tumors associated with leukocytosis include various types of malignancies. In epithelial cancers, the expression of G-CSF has been associated with poor differentiation and invasiveness [1–3]. However, it is a rare event among soft-tissue tumors for leukocytosis to be associated with an elevated level of serum G-CSF. Furthermore, although malignant fibrous histiocytoma (MFH), which is characterized by the absence of any distinct differentiation, has been reported to be accompanied by leukocytosis [4–6], this is extremely rare in the case of soft-tissue tumors with specific differentiation.
Summary of blood data
Days from OPE
G-CSF(pg/ml) [normal, <8 pg/ml]
Expression of G-CSF (anti-G-CSF [Ab1], Calbiochem, San Diego CA, USA) failed to be detected not only in the well-differentiated lipoma-like liposarcoma components, but also in the dedifferentiated components, immunohistochemically (data not shown).
The leukocytosis seen in the current case with dedifferentiated liposarcoma seemed to be due to stimulation by the tumor-produced G-CSF, on the basis that both the leukocytosis and the elevated level of G-CSF disappeared after the tumor was resected. In a previous report, leukocytosis appeared at an advanced stage, as characterized by poorly differentiated adenocarcinoma, not in the early stage, as characterized by well-differentiated adenocaricnoma, in the same lesion of gastric cancer. In that gastric cancer case, immunopositivity of G-CSF was only seen in the poorly differentiated adenocarcinoma, not in the well-differentiated adenocarcinoma. It is thus possible that histological changes may influence the acquisition of G-CSF-producing ability . In the current study, immunohistochemical study failed to detect any expression of G-CSF. It would seem that G-CSF-producing ability was acquired during the course of tumor progression, because leukocytosis appeared after noticeable tumor growth. It is also possible that the components of G-CSF-producing cells are heterogeneous in the tumor. Neoplastic cells in unexamined histological sections may express G-CSF, and an immunohistochemical study would have detected G-CSF expression.
In the English literature, including the current case, there have been 6 cases of liposarcoma accompanied by leukocytosis and associated with G-CSF expression [8–12]. Gender distribution was 3 males and 3 females, while the average age was 64.7 (range; 50–77) years. The sites were the following; retroperitoneum in 4 cases, mesenterium in 1 case and upper arm in 1 case. The subtype of these liposarcoma cases was dedifferentiated liposarcoma in 4 cases [10–12] and pleomorphic liposarcoma in 2 cases [8, 9]. Pleomorphic liposarcoma showed the features of pleomorphic sarcoma, mimicking MFH, and at least focally contained typical multivacuolated lipoblasts. In the case of epithelial tumors, G-CSF-producing tumors have been reported to be associated with poor differentiation [1–3]. Up until now, there have been no reported cases of well-differentiated liposarcoma with leukocytosis. Therefore, it may also be true that G-CSF expression is associated with undifferentiated liposarcoma, including both dedifferentiated liposarcoma and pleomorphic liposarcoma. Furthermore, it might be better to search for dedifferentiated components in an effort to provide a possible diagnosis of dedifferentiated liposarcoma, when well-differentiated liposarcoma is accompanied by leukocytosis.
MFH has been reported to be accompanied by leukocytosis, previously [4–6]. The diagnostic criteria of MFH are defined as "pleomorphic spindle cell sarcoma with no distinct line of differentiation". The diagnosis of MFH is commonly made by exclusion of other definitive sarcomas, such as liposarcoma and leiomyosarcoma. Recently, after reassessment of pleomorphic sarcomas, the tumors in a certain number of cases have been proved to be specific sarcomas other than MFH. Therefore, there is the possibility that the reported case of MFH with leukocytosis actually had a liposarcoma lineage. In addition, among soft-tissue tumors with specific differentiation, there seem to be no reported cases with leukocytosis, besides liposarcoma. The association between G-CSF production and undifferentiated liposarcoma formation implies that they share the same signaling pathways in part.
In epithelial cancers, G-CSF expression has been associated with poor differentiation and invasiveness [1–3]. Moreover, G-CSF expression was reported to be linked to poor prognosis in patients with lung carcinoma . G-CSF has been shown to stimulate tumor cell growth and migration in vitro [14–17]. In a similar manner, G-CSF may have contributed to the aggressive behavior of dedifferentiated liposarcoma in the current case. A transcription factor STAT3 is a key mediator of G-CSF signaling. STAT3 potently promotes proliferation, survival, invasion and angiogenic effects through regulation of multiple gene products [18–21]. Survivin is one of the STAT3-regulated genes, and has an important function in regulating the growth of cancer cells . It has been indicated that G-CSF potently activates STAT3 and STAT3-dependent survivin expression in bladder cancer cells . Further examination would be necessary to confirm whether or not this mechanism holds true for liposarcoma.
In this report, we present a case of dedifferentiated liposarcoma with leukocytosis. The leukocytosis seemed to be associated with an elevated level of serum G-CSF. We would like to propose a possible association between G-CSF-producing soft-tissue tumors and an undifferentiated liposarcoma lineage, such as dedifferentiated liposarcoma or pleomorphic liposarcoma.
The patient's family was informed that data from the case would be submitted for publication, and the family members gave their consent.
The English used in this manuscript was revised by Miss K. Miller (Royal English Language Centre, Fukuoka, Japan).
- Savarese TM, Mitchell K, McQuain C, Campbell CL, Guardiani R, Wuu J, Ollari C, Reale F, Nelson BE, Chen A, Quesenberry PJ: Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer Lett. 2001, 162 (1): 105-115. 10.1016/S0304-3835(00)00623-6.View ArticlePubMedGoogle Scholar
- Chakraborty A, White SM, Guha S: Granulocyte colony-stimulating receptor promotes beta1-integrin-mediated adhesion and invasion of bladder cancer cells. Urology. 2006, 68 (1): 208-213. 10.1016/j.urology.2006.01.046.View ArticlePubMedGoogle Scholar
- Hirai K, Kumakiri M, Fujieda S, Sunaga H, Lao LM, Imamura Y, Ueda K, Fukuda M: Expression of granulocyte colony-stimulating factor and its receptor in epithelial skin tumors. J Dermatol Sci. 2001 , 25 (3): 179-188. 10.1016/S0923-1811(00)00131-6.View ArticlePubMedGoogle Scholar
- Hamada T, Komiya S, Hiraoka K, Zenmyo M, Morimatsu M, Inoue A: IL-6 in a pleomorphic type of malignant fibrous histiocytoma presenting high fever. Hum Pathol. 1998, 29 (7): 758-761. 10.1016/S0046-8177(98)90288-X.View ArticlePubMedGoogle Scholar
- Melhem MF, Meisler AI, Saito R, Finley GG, Hockman HR, Koski RA: Cytokines in inflammatory malignant fibrous histiocytoma presenting with leukemoid reaction. Blood. 1993, 82 (7): 2038-2044.PubMedGoogle Scholar
- Mayumi E, Okuno T, Ogawa T, Kurata K, Ishioka H, Hamamoto H, Ishiki K, Maga T, Okamoto T, Yoshida T, Ogura Y: Malignant fibrous histiocytoma of soft tissue producing granulocyte colony-stimulating factor. Intern Med. 2001, 40 (6): 536-540.View ArticlePubMedGoogle Scholar
- Yamano T, Morii E, Ikeda J, Aozasa K: Granulocyte colony-stimulating factor production and rapid progression of gastric cancer after histological change in the tumor. Jpn J Clin Oncol. 2007, 37 (10): 793-796. 10.1093/jjco/hym094.View ArticlePubMedGoogle Scholar
- Matsumoto M, Yazawa Y, Kanzaki M: An autopsy case of liposarcoma with granulocytic leukemoid reaction. Acta Pathol Jpn. 1976, 26 (3): 399-408.PubMedGoogle Scholar
- Nakamura A, Tanaka S, Takayama H, Sakamoto M, Ishii H, Kusano M, Onizuka Y, Ota S, Mitamura K: A mesenteric liposarcoma with production of granulocyte colony-stimulating factor. Intern Med. 1998, 37 (10): 884-890.View ArticlePubMedGoogle Scholar
- Hisaoka M, Tsuji S, Hashimoto H, Aoki T, Uriu K: Dedifferentiated liposarcoma with an inflammatory malignant fibrous histiocytoma-like component presenting a leukemoid reaction. Pathol Int. 1997, 47 (9): 642-646.View ArticlePubMedGoogle Scholar
- Nasser SM, Choudry UH, Nielsen GP, Ott MJ: A leukemoid reaction in a patient with a dedifferentiated liposarcoma. Surgery. 2001, 129 (6): 765-767. 10.1067/msy.2001.109498.View ArticlePubMedGoogle Scholar
- des Guetz G, Mariani P, Freneaux P, Pouillart P: Paraneoplastic syndromes in cancer: Case 2. Leucocytosis associated with liposarcoma recurrence: original presentation of liposarcoma recurrence. J Clin Oncol. 2004, 22 (11): 2242-2243. 10.1200/JCO.2004.08.019.View ArticlePubMedGoogle Scholar
- Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K: Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer. 2001, 92 (9): 2399-2405. 10.1002/1097-0142(20011101)92:9<2399::AID-CNCR1588>3.0.CO;2-W.View ArticlePubMedGoogle Scholar
- Mueller MM, Herold-Mende CC, Riede D, Lange M, Steiner HH, Fusenig NE: Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol. 1999, 155 (5): 1557-1567.PubMed CentralView ArticlePubMedGoogle Scholar
- Mueller MM, Fusenig NE: Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progression. Int J Cancer. 1999, 83 (6): 780-789. 10.1002/(SICI)1097-0215(19991210)83:6<780::AID-IJC14>3.0.CO;2-C.View ArticlePubMedGoogle Scholar
- Obermueller E, Vosseler S, Fusenig NE, Mueller MM: Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res. 2004, 64 (21): 7801-7812. 10.1158/0008-5472.CAN-03-3301.View ArticlePubMedGoogle Scholar
- Pei XH, Nakanishi Y, Takayama K, Bai F, Hara N: Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br J Cancer. 1999, 79 (1): 40-46. 10.1038/sj.bjc.6690009.PubMed CentralView ArticlePubMedGoogle Scholar
- Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006, 12 (1): 11-19. 10.1158/1078-0432.CCR-04-1752.View ArticlePubMedGoogle Scholar
- Coppo P, Flamant S, De Mas V, Jarrier P, Guillier M, Bonnet ML, Lacout C, Guilhot F, Vainchenker W, Turhan AG: BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol. 2006, 134 (2): 171-179. 10.1111/j.1365-2141.2006.06161.x.View ArticlePubMedGoogle Scholar
- Yin W, Cheepala S, Roberts JN, Syson-Chan K, DiGiovanni J, Clifford JL: Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol Cancer. 2006 , 5 (): 15-23. 10.1186/1476-4598-5-15.PubMed CentralView ArticlePubMedGoogle Scholar
- Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos AS, Carter B, Turkson J, Jove R: Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther. 2006 , 5 (3): 621-629. 10.1158/1535-7163.MCT-05-0268.View ArticlePubMedGoogle Scholar
- Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005 , 5 (11): 876-885. 10.1038/nrc1736.View ArticlePubMedGoogle Scholar
- Chakraborty A, Guha S: Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells. Urology. 2007, 69 (6): 1210-1215. 10.1016/j.urology.2007.02.035.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.